New Report Shows Life Sciences as a Major Economic and Innovation Engine for Georgia

ATLANTA–(BUSINESS WIRE)–According to a new industry report released by the Center for Global Health Innovation (The Center) and TEConomy Partners, a global leader in research and analysis, Georgia’s life sciences industry has experienced strong and steady employment growth in recent years, outpacing even the rapidly growing national industry in its private sector industrial components and…

Read More

Georgia Tech is expanding Science Square. The first building just sold.

As economic headwinds continue to complicate office deals in Atlanta, the only completed building part of Georgia Tech’s Science Square has traded hands.  Ancora Partners, which is headquartered in Durham, North Carolina, paid $85 million to acquire the five-story, 128,000-square-foot building, according to Fulton County property deeds. This value is more than 25% higher than…

Read More

Five life sciences trends to watch for in 2023

Here’s the good news first – when it comes to deal flow and M&A activity, life sciences companies have been on a tear in the past couple of years. Just this year alone, among the largest biotech deals, Pfizer Inc. (NYSE: PFE) bought Biohaven Pharma for $12 billion, Bristol-Myers Squibb (NYSE: BMY) bought Turning Point for $4 billion and…

Read More

U.S. biotech is a major economic driver with a broad range, report says

The U.S. biotech sector is a vital economic engine in all 50 states, providing 2.1 million jobs and a $2.9 trillion impact on the economy in 2021, according to a comprehensive report published today. The report, produced by the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) in partnership with TEConomy, gives extensive data…

Read More

Gov. Kemp Announces Appointments to Rare Disease Advisory Council

Atlanta, GA – Governor Brian P. Kemp today announced his appointments to the Georgia Rare Disease Advisory Council, created by House Bill 918. The Council is comprised of 16 qualified professionals, persons living with rare diseases, and caregivers appointed by the Governor, Lieutenant Governor, and Speaker of the House. It will advise the General Assembly and other…

Read More

GeoVax Announces $10 Million Private Placement

ATLANTA, GA, January 14, 2022 — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a securities purchase agreement with a single institutional investor to raise approximately $10.0 million through the private placement of 707,484 shares of common stock, 2,360,000 pre-funded…

Read More

CMS’ Attempt to Restrict Patient Access to Alzheimer’s Drug Sets “Dangerous and Far-Reaching” Precedent

Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement in response to the Centers for Medicare and Medicaid Services’ (CMS) proposed National Coverage Determination (NCD) to restrict coverage for drugs used to treat patient suffering from Alzheimer’s: “The announcement by CMS sets a dangerous and far-reaching precedent for…

Read More

GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer

ATLANTA, GA, January 11, 2022 — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the appointment of Kelly T. McKee, Jr., M.D., M.P.H., to serve as the Company’s Chief Medical Officer (CMO). Dr. McKee brings over 30 years of experience in research and development, with…

Read More

GeoVax Receives Notice of Allowance for Ebola Vaccine Patent

Single-dose of GEO-EM01 Provided 100% Protection in Lethal Challenge Evaluation ATLANTA, GA, October 14, 2021 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No. 15/543,139 entitled “Replication-Deficient…

Read More